A kind of pharmaceutical composition and application for alleviating or eliminating opioid withdrawal syndrome

A composition and syndrome technology, applied in the fields of addiction medicine and neurobiology, can solve the problems of poor medication compliance and medication experience of patients, poor clinical application effect, and long withdrawal time, so as to improve medication compliance and Medication experience, obvious clinical advantages and, efficacy in eliminating withdrawal symptoms

Active Publication Date: 2022-01-21
SHENZHEN SCIENCARE MEDICAL INDUSTRIES CO. LTD.
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the invention takes a long time to withdraw, the patient's medication compliance and medication experience are poor, and the clinical application effect is poor.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of pharmaceutical composition and application for alleviating or eliminating opioid withdrawal syndrome
  • A kind of pharmaceutical composition and application for alleviating or eliminating opioid withdrawal syndrome
  • A kind of pharmaceutical composition and application for alleviating or eliminating opioid withdrawal syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-3

[0037] Embodiment 1-3 A compound tablet for alleviating or eliminating opioid withdrawal syndrome

[0038] The prescription of a compound tablet for alleviating or eliminating opioid withdrawal syndrome according to Embodiment 1-3 is shown in Table 1.

[0039] Table 1 Prescription of a compound tablet for alleviating or eliminating opioid withdrawal syndrome (each tablet contains / mg)

[0040]

[0041]

Embodiment 4-10

[0042] Embodiment 4-10 A compound tablet for alleviating or eliminating opioid withdrawal syndrome

[0043] Table 2 shows the prescription of a compound tablet for alleviating or eliminating opioid withdrawal syndrome in Examples 4-10.

[0044] Table 2 Prescription of a compound tablet for alleviating or eliminating opioid withdrawal syndrome (each containing / mg)

[0045]

[0046] The preparation method of described compound tablet, comprises the following steps:

[0047] (1) dissolving the clonidine hydrochloride of the prescribed amount in water, sieving with the prescribed amount of microcrystalline cellulose after granulation, and drying to obtain granules;

[0048] (2) Mix the granules obtained in step (1) with the prescribed amount of tramadol hydrochloride and lactose monohydrate, then add the prescribed amount of silicon dioxide and magnesium stearate to mix, compress into tablets and coat, to obtain the obtained Description of compound tablets.

experiment example 2

[0086] Experimental Example 2. Main Pharmacodynamics Study on Inhibition of Morphine Withdrawal Symptoms by Drugs

[0087] (1) Mouse jumping test

[0088] Mice were randomly divided into blank control group and drug group 1-12 according to body weight, wherein, drug group 1-12 (respectively administer the compound tablet prepared by embodiment 1-10 and the single tablet prepared by comparative example 1-2), They were divided into low-dose group, middle-dose group and high-dose group, with 10 rats in each group. Each group was intraperitoneally injected with morphine, 6 times a day, the dosage was 10mg / kg / time on the first day, 10mg / kg / time on the 2nd-3rd day, 50 minutes after the last injection of morphine, the low dose group of the drug , middle-dose group and high-dose group were administered intragastrically at doses of 36mg / kg, 72mg / kg, and 143mg / kg, and the blank control group was given an equal volume of normal saline. After 30 minutes of intragastric administration, ea...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pharmaceutical composition and application for alleviating or eliminating opioid withdrawal syndrome. The pharmaceutical composition comprises clonidine hydrochloride and tramadol hydrochloride with a mass ratio of 0.01-0.8:40-60, and the Application of the pharmaceutical composition in the preparation of drugs for alleviating or eliminating opioid withdrawal syndrome. The present invention is more suitable for the detoxification of patients with opioid drug abuse, with good effect, short time, 3-5 days to complete, safe and effective, easy to operate, has obvious clinical advantages and curative effect, and can improve patients' medication compliance and medication experience, Prevent abuse.

Description

technical field [0001] The invention relates to the technical fields of addiction medicine and neurobiology, in particular to a pharmaceutical composition and application for alleviating or eliminating opioid withdrawal syndrome. Background technique [0002] Drug abuse addiction has become a public hazard in the world. It not only endangers the physical and mental health of addicts, but also seriously interferes with social security and productivity development. At present, comprehensive medical, psychological, and social measures are recommended for the treatment of opioid dependence, including stopping drug abuse, detoxification treatment for withdrawal symptoms, rehabilitation and prevention for psychological dependence and other physical, psychological, and social function impairments Drug abuse treatment, and finally realize the rehabilitation and reintegration of drug addicts into society. During treatment, the severity of drug dependence should be determined first b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4168A61K31/137A61K9/28A61K47/38A61K47/26A61K47/04A61P25/36
CPCA61K31/4168A61K31/137A61K9/2054A61K9/2009A61K9/2018A61K9/28A61P25/36A61K2300/00
Inventor 梁铮林尹述贵颜携国王实强张涛
Owner SHENZHEN SCIENCARE MEDICAL INDUSTRIES CO. LTD.
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products